ALS-MND is our leading clinical program in neurodegeneration; however Parkinson’s and Alzheimer’s disease are also coming into sharp focus with some extraordinary new data directly related to IC14.
This new publication of a landmark paper in the prestigious Nature family of journals by our close collaborators at Houston Methodist Neurological Institute, led by our colleague and friend, Dr. Stan Appel. This research over the past decade shows the intimate link between CD14, the molecular target of IC14, and the rate of progression of ALS-MND. It also adds to the overwhelming evidence showing that this is a multi-system, multi-factorial inflammatory disorder, and not an isolated disease of the central nervous system.